Calculation
Net profit margin | = | 100 | × | Net income (loss)1 | ÷ | Product sales1 | |
---|---|---|---|---|---|---|---|
Dec 31, 2022 | 45.36% | = | 100 | × | 8,362) | ÷ | 18,435) |
Dec 31, 2021 | 69.04% | = | 100 | × | 12,202) | ÷ | 17,675) |
Dec 31, 2020 | -373.77% | = | 100 | × | (747) | ÷ | 200) |
Dec 31, 2019 | — | = | 100 | × | (514) | ÷ | —) |
Dec 31, 2018 | — | = | 100 | × | (385) | ÷ | —) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$ in millions
Comparison to Competitors
Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Zoetis Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2022 | 45.36% | 20.39% | 26.42% | 13.71% | 22.91% | 21.88% | 17.02% | 18.90% | 24.49% | 31.27% | 35.64% | 15.47% | 26.16% |
Dec 31, 2021 | 69.04% | 20.54% | 24.25% | 15.08% | 21.84% | 19.71% | 23.05% | 22.26% | 26.79% | 27.04% | 50.25% | 19.70% | 26.20% |
Dec 31, 2020 | -373.77% | 10.08% | 29.97% | -21.20% | 16.36% | 25.24% | 0.51% | 17.82% | 14.72% | 22.95% | 41.35% | 19.79% | 24.54% |
Dec 31, 2019 | — | 23.69% | 35.32% | 13.15% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 23.96% |
Dec 31, 2018 | — | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 24.52% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Dec 31, 2022 | 45.36% | 22.40% |
Dec 31, 2021 | 69.04% | 23.35% |
Dec 31, 2020 | -373.77% | 13.81% |
Dec 31, 2019 | — | 23.18% |
Dec 31, 2018 | — | 19.48% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc. | Health Care | |
---|---|---|
Dec 31, 2022 | 45.36% | 10.26% |
Dec 31, 2021 | 69.04% | 10.89% |
Dec 31, 2020 | -373.77% | 7.77% |
Dec 31, 2019 | — | 10.20% |
Dec 31, 2018 | — | 9.25% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).